Europe’s research-based association warns that EU pharmaceutical sandbox plans could face fresh scrutiny from national ...

Asia-Pacific OTC sales grew just 1.5% in the 12 months to June, IQVIA told the APSMI Summit in Bali, with cough and cold the ...

Disclosed priority review voucher sales have hit a record $1.78bn across nine deals this year, with average prices at their ...

Edwards Lifesciences reported 11.2% constant currency sales growth for the third quarter of 2026, bringing sales for the ...

An FDA official said the new council will coordinate supply chain work across product areas, but visibility will vary by ...

The biotech announced positive topline results from its Phase III study in the eye condition, which lacks FDA-approved ...

A pilot shows the UK’s guidance on inclusion and diversity plans is steering study sponsors in the right direction, but ...

FDA’s practice of deciding forfeiture only when a later applicant seeks approval leaves first-filers guessing for years, ...

However, Bourla acknowledged Democrats likely will investigate aspects of the MFN deals when they take control in Congress.

November will see a plethora of medical conferences, including the AHA and ACR, plus US FDA decisions on 12 novel drug applications, among other investor meetings.

Sean Keveney agreed to stay in the job until a successor is found and a transition is completed, but he could be one of ...

After an earlier knockback, Dr Reddy’s has secured approval from Brazil’s Anvisa for its semaglutide generic. But with ...